Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department
•The prevalence of SARS-CoV-2 in blood from patients with COVID-19 was determined.•SARS-CoV-2 was found in 5.9 % of the tested patients.•Plasma should not be used as primary sample to identify SARS-CoV-2 infection. Correct and reliable identification of SARS-CoV-2 in COVID-19 suspected patients is e...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2020-12, Vol.133, p.104655-104655, Article 104655 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104655 |
|---|---|
| container_issue | |
| container_start_page | 104655 |
| container_title | Journal of clinical virology |
| container_volume | 133 |
| creator | Nijhuis, R.H.T. Russcher, A. de Jong, G.J. Jong, E. Herder, G.J.M. Remijn, J.A. Verweij, S.P. |
| description | •The prevalence of SARS-CoV-2 in blood from patients with COVID-19 was determined.•SARS-CoV-2 was found in 5.9 % of the tested patients.•Plasma should not be used as primary sample to identify SARS-CoV-2 infection.
Correct and reliable identification of SARS-CoV-2 in COVID-19 suspected patients is essential for diagnosis. Respiratory samples should always be tested with real-time PCR for SARS-CoV-2. In addition, blood samples have been tested, but without consistent results and therefore the added value of this sample type is unknown. The aim of this study was to determine the prevalence of SARS-CoV-2 by real-time PCR in blood samples obtained from PCR-proven COVID-19 patients and in addition to elaborate on the potential use of blood for diagnostics. In this single center study, blood samples drawn from patients at the emergency department with proven COVID-19 infection based on a positive SARS-CoV-2 PCR in respiratory samples were tested for the presence of SARS-CoV-2. Samples from 118 patients were selected, of which 102 could be included in the study (median age was 65 (IQR 10), 65.7 % men). In six (5.9 %) of the tested samples, SARS-CoV-2 was identified by real-time PCR.
In conclusion, SARS-CoV-2 can be detected by real-time PCR in plasma samples from patients with proven COVID-19, but only in a minority of the patients. Plasma should therefore not be used as primary sample in an acute phase setting to identify SARS-CoV-2 infection. These findings are important to complete the knowledge on possible sample types to test to diagnose COVID-19. |
| doi_str_mv | 10.1016/j.jcv.2020.104655 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33069846</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1386653220303978</els_id><sourcerecordid>2452099069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-8dafa91f8cf87fbe211c47cb836242b38997b380508d2e7f1ad17c940cb210b73</originalsourceid><addsrcrecordid>eNqNkV2L1DAUhoso7rr6A7yRXApLx3w0TYIgLPVrYWDB1b0NaXo6m6FtapKZZf-9KTMOeiPeJCfJ-74nyVMUrwleEUzqd9vV1u5XFNNlXdWcPynOiRSs5KoWT3PNZF3WnNGz4kWMW4wJZ5V4Xpwxhmslq_q8aNf-Ac0B9maAyQLyPbq9-nZbNv6upMhNaB5MHM2y39zcXX8siUKzSQ6mFBdfzIWbNih5lO4BwQhhk4MeUQezCWnMxy-LZ70ZIrw6zhfFj8-fvjdfy_XNl-vmal3aipNUys70RpFe2l6KvgVKiK2EbSWraUVbJpUSecQcy46C6InpiLCqwralBLeCXRQfDrnzrh2hs7l1MIOegxtNeNTeOP33yeTu9cbvteCM1ZzkgLfHgOB_7iAmPbpoYRjMBH4XNa04xUrlr8tScpDa4GMM0J_aEKwXNnqrMxu9sNEHNtnz5s_7nRy_YWSBPAgeoPV9tG4hcpJhjLmSggiaKyIalzIGPzV-N6Vsvfx_a1a_P6gh49g7CPro6FwAm3Tn3T_e8QvVYb_s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452099069</pqid></control><display><type>article</type><title>Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Nijhuis, R.H.T. ; Russcher, A. ; de Jong, G.J. ; Jong, E. ; Herder, G.J.M. ; Remijn, J.A. ; Verweij, S.P.</creator><creatorcontrib>Nijhuis, R.H.T. ; Russcher, A. ; de Jong, G.J. ; Jong, E. ; Herder, G.J.M. ; Remijn, J.A. ; Verweij, S.P.</creatorcontrib><description>•The prevalence of SARS-CoV-2 in blood from patients with COVID-19 was determined.•SARS-CoV-2 was found in 5.9 % of the tested patients.•Plasma should not be used as primary sample to identify SARS-CoV-2 infection.
Correct and reliable identification of SARS-CoV-2 in COVID-19 suspected patients is essential for diagnosis. Respiratory samples should always be tested with real-time PCR for SARS-CoV-2. In addition, blood samples have been tested, but without consistent results and therefore the added value of this sample type is unknown. The aim of this study was to determine the prevalence of SARS-CoV-2 by real-time PCR in blood samples obtained from PCR-proven COVID-19 patients and in addition to elaborate on the potential use of blood for diagnostics. In this single center study, blood samples drawn from patients at the emergency department with proven COVID-19 infection based on a positive SARS-CoV-2 PCR in respiratory samples were tested for the presence of SARS-CoV-2. Samples from 118 patients were selected, of which 102 could be included in the study (median age was 65 (IQR 10), 65.7 % men). In six (5.9 %) of the tested samples, SARS-CoV-2 was identified by real-time PCR.
In conclusion, SARS-CoV-2 can be detected by real-time PCR in plasma samples from patients with proven COVID-19, but only in a minority of the patients. Plasma should therefore not be used as primary sample in an acute phase setting to identify SARS-CoV-2 infection. These findings are important to complete the knowledge on possible sample types to test to diagnose COVID-19.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2020.104655</identifier><identifier>PMID: 33069846</identifier><language>eng</language><publisher>AMSTERDAM: Elsevier B.V</publisher><subject>Aged ; Aged, 80 and over ; Blood ; COVID ; COVID-19 - blood ; COVID-19 - diagnosis ; COVID-19 Nucleic Acid Testing ; Emergency Service, Hospital ; Female ; Humans ; Life Sciences & Biomedicine ; Male ; Middle Aged ; Netherlands ; Plasma ; Prevalence ; RNA, Viral - blood ; SARS-CoV-2 ; SARS-CoV-2 - genetics ; SARS-CoV-2 - isolation & purification ; Science & Technology ; Short Communication ; Viremia ; Viremia - diagnosis ; Virology</subject><ispartof>Journal of clinical virology, 2020-12, Vol.133, p.104655-104655, Article 104655</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>11</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000598717200017</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c451t-8dafa91f8cf87fbe211c47cb836242b38997b380508d2e7f1ad17c940cb210b73</citedby><cites>FETCH-LOGICAL-c451t-8dafa91f8cf87fbe211c47cb836242b38997b380508d2e7f1ad17c940cb210b73</cites><orcidid>0000-0003-4203-3858</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcv.2020.104655$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3554,27933,27934,28257,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33069846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nijhuis, R.H.T.</creatorcontrib><creatorcontrib>Russcher, A.</creatorcontrib><creatorcontrib>de Jong, G.J.</creatorcontrib><creatorcontrib>Jong, E.</creatorcontrib><creatorcontrib>Herder, G.J.M.</creatorcontrib><creatorcontrib>Remijn, J.A.</creatorcontrib><creatorcontrib>Verweij, S.P.</creatorcontrib><title>Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department</title><title>Journal of clinical virology</title><addtitle>J CLIN VIROL</addtitle><addtitle>J Clin Virol</addtitle><description>•The prevalence of SARS-CoV-2 in blood from patients with COVID-19 was determined.•SARS-CoV-2 was found in 5.9 % of the tested patients.•Plasma should not be used as primary sample to identify SARS-CoV-2 infection.
Correct and reliable identification of SARS-CoV-2 in COVID-19 suspected patients is essential for diagnosis. Respiratory samples should always be tested with real-time PCR for SARS-CoV-2. In addition, blood samples have been tested, but without consistent results and therefore the added value of this sample type is unknown. The aim of this study was to determine the prevalence of SARS-CoV-2 by real-time PCR in blood samples obtained from PCR-proven COVID-19 patients and in addition to elaborate on the potential use of blood for diagnostics. In this single center study, blood samples drawn from patients at the emergency department with proven COVID-19 infection based on a positive SARS-CoV-2 PCR in respiratory samples were tested for the presence of SARS-CoV-2. Samples from 118 patients were selected, of which 102 could be included in the study (median age was 65 (IQR 10), 65.7 % men). In six (5.9 %) of the tested samples, SARS-CoV-2 was identified by real-time PCR.
In conclusion, SARS-CoV-2 can be detected by real-time PCR in plasma samples from patients with proven COVID-19, but only in a minority of the patients. Plasma should therefore not be used as primary sample in an acute phase setting to identify SARS-CoV-2 infection. These findings are important to complete the knowledge on possible sample types to test to diagnose COVID-19.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Blood</subject><subject>COVID</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 Nucleic Acid Testing</subject><subject>Emergency Service, Hospital</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Netherlands</subject><subject>Plasma</subject><subject>Prevalence</subject><subject>RNA, Viral - blood</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Science & Technology</subject><subject>Short Communication</subject><subject>Viremia</subject><subject>Viremia - diagnosis</subject><subject>Virology</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><recordid>eNqNkV2L1DAUhoso7rr6A7yRXApLx3w0TYIgLPVrYWDB1b0NaXo6m6FtapKZZf-9KTMOeiPeJCfJ-74nyVMUrwleEUzqd9vV1u5XFNNlXdWcPynOiRSs5KoWT3PNZF3WnNGz4kWMW4wJZ5V4Xpwxhmslq_q8aNf-Ac0B9maAyQLyPbq9-nZbNv6upMhNaB5MHM2y39zcXX8siUKzSQ6mFBdfzIWbNih5lO4BwQhhk4MeUQezCWnMxy-LZ70ZIrw6zhfFj8-fvjdfy_XNl-vmal3aipNUys70RpFe2l6KvgVKiK2EbSWraUVbJpUSecQcy46C6InpiLCqwralBLeCXRQfDrnzrh2hs7l1MIOegxtNeNTeOP33yeTu9cbvteCM1ZzkgLfHgOB_7iAmPbpoYRjMBH4XNa04xUrlr8tScpDa4GMM0J_aEKwXNnqrMxu9sNEHNtnz5s_7nRy_YWSBPAgeoPV9tG4hcpJhjLmSggiaKyIalzIGPzV-N6Vsvfx_a1a_P6gh49g7CPro6FwAm3Tn3T_e8QvVYb_s</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Nijhuis, R.H.T.</creator><creator>Russcher, A.</creator><creator>de Jong, G.J.</creator><creator>Jong, E.</creator><creator>Herder, G.J.M.</creator><creator>Remijn, J.A.</creator><creator>Verweij, S.P.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4203-3858</orcidid></search><sort><creationdate>20201201</creationdate><title>Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department</title><author>Nijhuis, R.H.T. ; Russcher, A. ; de Jong, G.J. ; Jong, E. ; Herder, G.J.M. ; Remijn, J.A. ; Verweij, S.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-8dafa91f8cf87fbe211c47cb836242b38997b380508d2e7f1ad17c940cb210b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Blood</topic><topic>COVID</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 Nucleic Acid Testing</topic><topic>Emergency Service, Hospital</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Netherlands</topic><topic>Plasma</topic><topic>Prevalence</topic><topic>RNA, Viral - blood</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Science & Technology</topic><topic>Short Communication</topic><topic>Viremia</topic><topic>Viremia - diagnosis</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nijhuis, R.H.T.</creatorcontrib><creatorcontrib>Russcher, A.</creatorcontrib><creatorcontrib>de Jong, G.J.</creatorcontrib><creatorcontrib>Jong, E.</creatorcontrib><creatorcontrib>Herder, G.J.M.</creatorcontrib><creatorcontrib>Remijn, J.A.</creatorcontrib><creatorcontrib>Verweij, S.P.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nijhuis, R.H.T.</au><au>Russcher, A.</au><au>de Jong, G.J.</au><au>Jong, E.</au><au>Herder, G.J.M.</au><au>Remijn, J.A.</au><au>Verweij, S.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department</atitle><jtitle>Journal of clinical virology</jtitle><stitle>J CLIN VIROL</stitle><addtitle>J Clin Virol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>133</volume><spage>104655</spage><epage>104655</epage><pages>104655-104655</pages><artnum>104655</artnum><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>•The prevalence of SARS-CoV-2 in blood from patients with COVID-19 was determined.•SARS-CoV-2 was found in 5.9 % of the tested patients.•Plasma should not be used as primary sample to identify SARS-CoV-2 infection.
Correct and reliable identification of SARS-CoV-2 in COVID-19 suspected patients is essential for diagnosis. Respiratory samples should always be tested with real-time PCR for SARS-CoV-2. In addition, blood samples have been tested, but without consistent results and therefore the added value of this sample type is unknown. The aim of this study was to determine the prevalence of SARS-CoV-2 by real-time PCR in blood samples obtained from PCR-proven COVID-19 patients and in addition to elaborate on the potential use of blood for diagnostics. In this single center study, blood samples drawn from patients at the emergency department with proven COVID-19 infection based on a positive SARS-CoV-2 PCR in respiratory samples were tested for the presence of SARS-CoV-2. Samples from 118 patients were selected, of which 102 could be included in the study (median age was 65 (IQR 10), 65.7 % men). In six (5.9 %) of the tested samples, SARS-CoV-2 was identified by real-time PCR.
In conclusion, SARS-CoV-2 can be detected by real-time PCR in plasma samples from patients with proven COVID-19, but only in a minority of the patients. Plasma should therefore not be used as primary sample in an acute phase setting to identify SARS-CoV-2 infection. These findings are important to complete the knowledge on possible sample types to test to diagnose COVID-19.</abstract><cop>AMSTERDAM</cop><pub>Elsevier B.V</pub><pmid>33069846</pmid><doi>10.1016/j.jcv.2020.104655</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-4203-3858</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2020-12, Vol.133, p.104655-104655, Article 104655 |
| issn | 1386-6532 1873-5967 |
| language | eng |
| recordid | cdi_pubmed_primary_33069846 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Aged Aged, 80 and over Blood COVID COVID-19 - blood COVID-19 - diagnosis COVID-19 Nucleic Acid Testing Emergency Service, Hospital Female Humans Life Sciences & Biomedicine Male Middle Aged Netherlands Plasma Prevalence RNA, Viral - blood SARS-CoV-2 SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification Science & Technology Short Communication Viremia Viremia - diagnosis Virology |
| title | Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T14%3A37%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20prevalence%20of%20SARS-CoV-2%20in%20plasma%20of%20COVID-19%20patients%20presenting%20to%20the%20emergency%20department&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Nijhuis,%20R.H.T.&rft.date=2020-12-01&rft.volume=133&rft.spage=104655&rft.epage=104655&rft.pages=104655-104655&rft.artnum=104655&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2020.104655&rft_dat=%3Cproquest_pubme%3E2452099069%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452099069&rft_id=info:pmid/33069846&rft_els_id=S1386653220303978&rfr_iscdi=true |